TriangleNCT00091260 · OUTCOME
Number of Patients Who Received Both CC-5013 and Dexamethasone and Had a Hematologic Response
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- participants
- Interval / dispersion
- Not reported
- Time frame
- 1 year
Groups in this outcome
Revlimid
lenalidomide 15 mg/day, for 21 days with 7 days rest (28 day cycle) with or without dexamethasone 20 mg daily (10 mg twice daily) on Days 1-4, 9-12, and 17-20 of every other 28-day cycle. dexamethasone: dexamethasone 20 mg daily (10 mg twice daily) on Days 1-4, 9-12, and 17-20 of every other 28-day cycle. lenalidomide: 15 mg/day, for 21 days with 7 days rest (28 day cycle) with or without dexamethasone
| Group | Source count |
|---|---|
| Revlimid | 43 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Revlimid | 26 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 26
- denoms
- counts
- group Id
- OG000
- value
- 43
- units
- Participants
- groups
- description
- lenalidomide 15 mg/day, for 21 days with 7 days rest (28 day cycle) with or without dexamethasone 20 mg daily (10 mg twice daily) on Days 1-4, 9-12, and 17-20 of every other 28-day cycle. dexamethasone: dexamethasone 20 mg daily (10 mg twice daily) on Days 1-4, 9-12, and 17-20 of every other 28-day cycle. lenalidomide: 15 mg/day, for 21 days with 7 days rest (28 day cycle) with or without dexamethasone
- id
- OG000
- title
- Revlimid
- param Type
- NUMBER
- reporting Status
- POSTED
- time Frame
- 1 year
- title
- Number of Patients Who Received Both CC-5013 and Dexamethasone and Had a Hematologic Response
- type
- SECONDARY
- unit Of Measure
- participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice